Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety

► Levomilnacipran is the more active enantiomer of the SNRI milnacipran. ► It is selective in vitro for NET and SERT versus 23 other targets. ► It inhibits NE and 5-HT reuptake in vitro with ∼2-fold greater potency at NET. ► The NE/5-HT ratio of reuptake inhibition in vitro is greater than for other SNRIs. ► It displays antidepressant/anxiolytic efficacy comparable to that of other SNRIs.